RAN to collaborate with Celgene on cancer therapeutics development
The RAN has recently signed a 3-year $25M agreement with the Celgene Corporation to develop next-generation, antibody-based cancer therapies with the option to enter into future license agreements. Collaboration will focus on novel high value cancer targets. Besides supporting the high throughput antibody generating pipelines, this agreement will enable setting up robotics for a battery of state of the art cell based assays. The capacity that can be achieved with regard to antibody generation and target validation is unmatched by any similar facility in the world.
Redox-based reagents for chemoselective methionine bioconjugation. (published on 2017 Feb 10)
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. (published on 2017 Jan 26)